ImmuPharma PLC (LON:IMM)‘s stock had its “buy” rating reissued by equities research analysts at Northland Capital Partners in a note issued to investors on Thursday. They currently have a GBX 181 ($2.44) price target on the stock. Northland Capital Partners’ target price indicates a potential upside of 275.13% from the company’s current price.

Separately, Northland Securities reaffirmed a “buy” rating and set a GBX 181 ($2.44) price target on shares of ImmuPharma PLC in a report on Thursday.

Shares of ImmuPharma PLC (LON:IMM) traded up 4.66% during trading on Thursday, hitting GBX 50.50. 185,789 shares of the stock were exchanged. The stock’s market cap is GBX 66.92 million. The firm has a 50 day moving average of GBX 49.53 and a 200-day moving average of GBX 52.68. ImmuPharma PLC has a 52-week low of GBX 31.44 and a 52-week high of GBX 70.32.

COPYRIGHT VIOLATION NOTICE: “ImmuPharma PLC (IMM) Stock Rating Reaffirmed by Northland Capital Partners” was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at

ImmuPharma PLC Company Profile

ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents.

Receive News & Ratings for ImmuPharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma PLC and related companies with's FREE daily email newsletter.